Child's Nervous System

, Volume 28, Issue 7, pp 1025–1032 | Cite as

Distinct genetic alterations in pediatric glioblastomas

  • Sun-ju Byeon
  • Jae Kyung Myung
  • Se Hoon Kim
  • Seung-Ki Kim
  • Ji Hoon Phi
  • Sung-Hye ParkEmail author
Original Paper



Pediatric high-grade tumors, especially glioblastomas (GBs), can be clinically devastating but are under-studied in comparison with adult GBs (aGBs). Molecular features of pediatric GBs (pGBs) are poorly understood and novel-targeted therapies have not been routinely used in pediatric patients with GBs.


Twenty-four non-brainstem pGBs were studied. To compare pGBs with aGBs, immunohistochemical staining and fluorescent in situ hybridization were performed in paraffin-embedded tissues. Microarray gene expression analyses were performed in snap-frozen tissues of four primary pGBs, six primary aGBs, and one non-neoplastic brain.


Immunohistochemial p16 loss was more frequent in pGBs, whereas p53, epidermal growth factor receptor, and phosphatase and tensin homolog loss were similar to that of aGBs. No case was isocitrate dehydrogenase (IDH)1 immunopositive or showed the IDH1 R132/IDH2 R172 mutation, suggesting primary GB. Microarray analysis revealed two pGB subtypes (A and B). Type B pGBs and aGBs had similar gene expression profiles; however, the profiles of type A pGBs differed from those of aGBs. In type A pGBs, we identified 90 up- and 63 down-regulated genes; platelet-derived growth factor receptor α polypeptide and CCND2 expression were significantly reduced, whereas they were up-regulated in aGBs.


Our study found two distinct pGB gene expression profiles: one similar to that of aGBs and the other different. We identified significantly up- and down-regulated genes in pGBs that may provide better targets for diagnostic, prognostic, and therapeutic uses; however, more studies are required to determine the classification and optimal treatment of pediatric patients with GBs.


Glioblastoma Pediatrics Molecular pathology Gene expression profile 



This research was supported by Basic Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (2011-0003666).

Conflict of interest

We have no conflicts of interest to declare.

Supplementary material

381_2012_1773_MOESM1_ESM.doc (310 kb)
ESM 1 (DOC 310 kb)


  1. 1.
    Arora RS, Alston RD, Eden TO, Estlin EJ, Moran A, Birch JM (2009) Age-incidence patterns of primary CNS tumors in children, adolescents, and adults in England. Neuro Oncol 11:403–413PubMedCrossRefGoogle Scholar
  2. 2.
    Suri V, Das P, Pathak P, Jain A, Sharma MC, Borkar SA, Suri A, Gupta D, Sarkar C (2009) Pediatric glioblastomas: a histopathological and molecular genetic study. Neuro Oncol 11:274–280PubMedCrossRefGoogle Scholar
  3. 3.
    Ganigi PM, Santosh V, Anandh B, Chandramouli BA, Sastry Kolluri VR (2005) Expression of p53, EGFR, pRb and bcl-2 proteins in pediatric glioblastoma multiforme: a study of 54 patients. Pediatr Neurosurg 41:292–299PubMedCrossRefGoogle Scholar
  4. 4.
    Kim B, Myung JK, Seo JH, Park CK, Paek SH, Kim DG, Jung HW, Park SH (2010) The clinicopathologic values of the molecules associated with the main pathogenesis of the glioblastoma. J Neurol Sci 294:112–118PubMedCrossRefGoogle Scholar
  5. 5.
    Bax DA, Little SE, Gaspar N, Perryman L, Marshall L, Viana-Pereira M, Jones TA, Williams RD, Grigoriadis A, Vassal G, Workman P, Sheer D, Reis RM, Pearson AD, Hargrave D, Jones C (2009) Molecular and phenotypic characterisation of paediatric glioma cell lines as models for preclinical drug development. PLoS One 4:e5209PubMedCrossRefGoogle Scholar
  6. 6.
    Karlbom AE, James CD, Boethius J, Cavenee WK, Collins VP, Nordenskjold M, Larsson C (1993) Loss of heterozygosity in malignant gliomas involves at least three distinct regions on chromosome 10. Hum Genet 92:169–174PubMedCrossRefGoogle Scholar
  7. 7.
    Ohgaki H, Kleihues P (2009) Genetic alterations and signaling pathways in the evolution of gliomas. Cancer Sci 100:2235–2241PubMedCrossRefGoogle Scholar
  8. 8.
    Packer RJ (1999) Primary central nervous system tumors in children. Curr Treat Options Neurol 1:395–408PubMedCrossRefGoogle Scholar
  9. 9.
    Packer RJ (1999) Brain tumors in children. Arch Neurol 56:421–425PubMedCrossRefGoogle Scholar
  10. 10.
    Yin D, Ogawa S, Kawamata N, Tunici P, Finocchiaro G, Eoli M, Ruckert C, Huynh T, Liu G, Kato M, Sanada M, Jauch A, Dugas M, Black KL, Koeffler HP (2009) High-resolution genomic copy number profiling of glioblastoma multiforme by single nucleotide polymorphism DNA microarray. Mol Cancer Res 7:665–677PubMedCrossRefGoogle Scholar
  11. 11.
    Sharma S, Free A, Mei Y, Peiper SC, Wang Z, Cowell JK (2010) Distinct molecular signatures in pediatric infratentorial glioblastomas defined by aCGH. Exp Mol Pathol 89:169–174PubMedCrossRefGoogle Scholar
  12. 12.
    Bax DA, Gaspar N, Little SE, Marshall L, Perryman L, Regairaz M, Viana-Pereira M, Vuononvirta R, Sharp SY, Reis-Filho JS, Stavale JN, Al-Sarraj S, Reis RM, Vassal G, Pearson AD, Hargrave D, Ellison DW, Workman P, Jones C (2009) EGFRvIII deletion mutations in pediatric high-grade glioma and response to targeted therapy in pediatric glioma cell lines. Clin Cancer Res 15:5753–5761PubMedCrossRefGoogle Scholar
  13. 13.
    Zarghooni M, Bartels U, Lee E, Buczkowicz P, Morrison A, Huang A, Bouffet E, Hawkins C (2010) Whole-genome profiling of pediatric diffuse intrinsic pontine gliomas highlights platelet-derived growth factor receptor alpha and poly (ADP-ribose) polymerase as potential therapeutic targets. J Clin Oncol 28:1337–1344PubMedCrossRefGoogle Scholar
  14. 14.
    Paugh BS, Qu C, Jones C, Liu Z, Adamowicz-Brice M, Zhang J, Bax DA, Coyle B, Barrow J, Hargrave D, Lowe J, Gajjar A, Zhao W, Broniscer A, Ellison DW, Grundy RG, Baker SJ (2010) Integrated molecular genetic profiling of pediatric high-grade gliomas reveals key differences with the adult disease. J Clin Oncol 28:3061–3068PubMedCrossRefGoogle Scholar
  15. 15.
    Nobusawa S, Stawski R, Kim YH, Nakazato Y, Ohgaki H (2011) Amplification of the PDGFRA, KIT and KDR genes in glioblastoma: a population-based study. Neuropathology 31:583–588PubMedCrossRefGoogle Scholar
  16. 16.
    Gaspar N, Marshall L, Perryman L, Bax DA, Little SE, Viana-Pereira M, Sharp SY, Vassal G, Pearson AD, Reis RM, Hargrave D, Workman P, Jones C (2010) MGMT-independent temozolomide resistance in pediatric glioblastoma cells associated with a PI3-kinase-mediated HOX/stem cell gene signature. Cancer Res 70:9243–9252PubMedCrossRefGoogle Scholar
  17. 17.
    Cappuzzo F, Hirsch FR, Rossi E, Bartolini S, Ceresoli GL, Bemis L, Haney J, Witta S, Danenberg K, Domenichini I, Ludovini V, Magrini E, Gregorc V, Doglioni C, Sidoni A, Tonato M, Franklin WA, Crino L, Bunn PA Jr, Varella-Garcia M (2005) Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 97:643–655PubMedCrossRefGoogle Scholar
  18. 18.
    Lee SH, Hwang TS, Koh Y-C, Kim WY, Han HS, Kim WS, Ko YS, Lim SD (2011) A consideration of MGMT gene promotor methylation analysis for glioblastoma using methylation-specific polymerase chain reaction and pyrosequencing. Korean J Pathol 45:21–29CrossRefGoogle Scholar
  19. 19.
    Noh S, Park EJ, Choi J, Lee S, Jang SJ, Kim SH (2011) Mutations in isocitrate dehydrogenase isoforms 1 and 2 are rare events in primary central nervous system and non-central nervous system diffuse large B cell lymphoma. Basic Appl Pathol 4:58–62CrossRefGoogle Scholar
  20. 20.
    Faury D, Nantel A, Dunn SE, Guiot MC, Haque T, Hauser P, Garami M, Bognar L, Hanzely Z, Liberski PP, Lopez-Aguilar E, Valera ET, Tone LG, Carret AS, Del Maestro RF, Gleave M, Montes JL, Pietsch T, Albrecht S, Jabado N (2007) Molecular profiling identifies prognostic subgroups of pediatric glioblastoma and shows increased YB-1 expression in tumors. J Clin Oncol 25:1196–1208PubMedCrossRefGoogle Scholar
  21. 21.
    Song KS, Phi JH, Cho BK, Wang KC, Lee JY, Kim DG, Kim IH, Ahn HS, Park SH, Kim SK (2010) Long-term outcomes in children with glioblastoma. J Neurosurg Pediatr 6:145–149PubMedCrossRefGoogle Scholar
  22. 22.
    Hales RK, Shokek O, Burger PC, Paynter NP, Chaichana KL, Quinones-Hinojosa A, Jallo GI, Cohen KJ, Song DY, Carson BS, Wharam MD (2010) Prognostic factors in pediatric high-grade astrocytoma: the importance of accurate pathologic diagnosis. J Neurooncol 99:65–71PubMedCrossRefGoogle Scholar
  23. 23.
    Lee JY, Park CK, Park SH, Wang KC, Cho BK, Kim SK (2011) MGMT promoter gene methylation in pediatric glioblastoma: analysis using MS-MLPA. Childs Nerv Syst 27:1877–1883PubMedCrossRefGoogle Scholar
  24. 24.
    Donson AM, Addo-Yobo SO, Handler MH, Gore L, Foreman NK (2007) MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma. Pediatr Blood Cancer 48:403–407PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2012

Authors and Affiliations

  • Sun-ju Byeon
    • 1
  • Jae Kyung Myung
    • 2
  • Se Hoon Kim
    • 3
  • Seung-Ki Kim
    • 4
  • Ji Hoon Phi
    • 5
  • Sung-Hye Park
    • 6
    Email author
  1. 1.Department of PathologySeoul Nation University HospitalSeoulRepublic of Korea
  2. 2.Department of PathologySeoul National University College of MedicineSeoulRepublic of Korea
  3. 3.Department of PathologyYonsei University College of MedicineSeoulRepublic of Korea
  4. 4.Division of Pediatric NeurosurgerySeoul National University Children’s Hospital, Seoul National University College of MedicineSeoulRepublic of Korea
  5. 5.Department of NeurosurgerySeoul National University, College of MedicineSeoulRepublic of Korea
  6. 6.Department of Pathology, and Neuroscience Research InstituteSeoul National University College of MedicineSeoulRepublic of Korea

Personalised recommendations